First-line zanidatamab plus chemotherapy leads to ‘practice-changing’ PFS and overall survival gains in a phase 3 study of HER2-positive advanced gastroesophageal adenocarcinoma.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/practice-changing-data-gastroesophageal-adenocarcinoma-2026a10000yp?src=rss
Author :
Publish date : 2026-01-12 12:00:00
Copyright for syndicated content belongs to the linked Source.
